Partner Content Partner Content KOL Mapping and Validation You’ve done your KOL Mapping, and you have been in a therapy area for a while. You may have gotten used to working with the same KOLs and Experts over and over again.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
